External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology SABCS 2023
Roche and Genentech at

SABCS 2023

December 05 - December 09
San Antonio, USA
sabcs.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
05:00 PM
Duration 180mins Hall 1
Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis
Loibl S, Mano MS, Untch M, Huang C-S, Mamounas EP, Wolmark N, Knott A, Siddiqui A, Boulet T, Nyawira B, Restuccia E, Geyer Jr CE
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:15 PM
Duration 180mins Hall 1
Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis
Komal L. Jhaveri
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.